Introduction {#s001}
============

M[olecular diagnostics]{.smallcaps} (MDx) have been available for the detection of infections for more than 20 years (Ehrlich and Greenberg, 1994; Marshall *et al.*, [@B20]) and have routinely been demonstrated to be superior to culture techniques (Ehrlich and Greenberg, 1994; Aul *et al.*, [@B1]); however, their adoption in clinical medicine has been limited by time and cost constraints (Zmistowski *et al.*, [@B36]) as well as by the lack of common diagnostic criteria and the lack of single-format tests that provide for unbiased panel-based and pan-domain testing (Ehrlich, [@B7]; Hall-Stoodley *et al.*, [@B15]; Zmistowski *et al.*, [@B36]). As MDx technology improves and cost barriers decrease, implementation of these tools is becoming more widespread. The current generation of computationally based nucleic acid tests has the ability to provide greater diagnostic accuracy more rapidly than culture-based methods while doing so more rapidly and efficiently (Kathju *et al.*, [@B19]; Tuttle *et al.*, [@B33]; Yun *et al.*, [@B35]; Boase *et al.*, [@B2]; Vento *et al.*, [@B34]; Nickel *et al.*, [@B22]). In particular, the polymerase chain reaction--electrospray ionization--time-of-flight mass spectrometry (PCR--ESI--TOF--MS) platform has shown promise in diagnosing orthopedic infections (Stoodley *et al.*, [@B32], [@B30]; Kathju *et al.*, [@B18]; Costerton *et al.*, [@B4]; Gallo *et al.*, [@B13]; Ehrlich *et al.*, [@B9]; Jacovides *et al.*, [@B17]; Howe *et al.*, [@B16]; Palmer *et al.*, [@B26]).

Rapid bacterial detection in sterile body fluid specimens is vitally important for many reasons. First, identifying whether or not bacteria are actually present provides important differential diagnostic information. Second, identifying the taxon of the invading pathogen provides information critical for aiding in identifying the likely source, that is, community acquired versus nosocomial. Third, identification of antibiotic resistance provides for the development of targeted antibiotic treatment regimens. Current microbiological techniques can take anywhere from 2 to 21 days to diagnose the presence of bacteria and provide an antibiogram. This can lead to prolonged treatment with broad-spectrum antibiotics or a lag in antibiotic administration until the cultures turn positive if infection is not suspected. MDx techniques have the ability to provide all of this information within hours, not days, as the genes for antibiotic resistance can be detected as well as the pathogens themselves (Ecker *et al.*, [@B6]; Ehrlich *et al.*, [@B9]).

Rapid MDx can play an important role in orthopedics as many bacterial infections, particularly chronic infections, are either difficult to detect using standard culture or are occult and do not provide the clinical signs and symptoms usually associated with acute infection (Ehrlich *et al.*, [@B9], [@B11]). One of the primary means by which bacteria persist in the human body is through the formation of complex differentiated bacterial communities, termed biofilms, which are recalcitrant to standard microbial culture and antibiotic treatments (Kathju *et al.*, [@B19]; Ehrlich *et al.*, [@B8]; Costerton *et al.*, [@B4]; Hall-Stoodley *et al.*, [@B15]; Boase *et al.*, [@B2]; Nickel *et al.*, [@B22]). Thus, culture-based techniques have high rates of false negatives compared with modern MDx techniques (Stoodley *et al.*, [@B32], [@B30]; Kathju *et al.*, [@B19], [@B18]; Costerton *et al.*, [@B4]; Gallo *et al.*, [@B13]; Tuttle *et al.*, [@B33]; Ehrlich *et al.*, [@B9]; Jacovides *et al.*, [@B17]; Kreft *et al.*, 2012; Boase *et al.*, [@B2]; Howe *et al.*, [@B16]; Vento *et al.*, [@B34]; Palmer *et al.*, [@B26]; Nickel *et al.*, [@B22]).

In orthopedics, synovial fluid analyses provide a great deal of information with regard to the biology of the joint, and useful clinical treatment algorithms have been implemented based on the findings. The likelihood of diagnosing septic arthritis increases with elevation in white blood count, percent neutrophils, and protein level, as well as a decrease in glucose level. Definitive diagnoses have classically relied on the presence of a positive culture and/or Gram stain. Unfortunately, the sensitivities of culture and Gram stain are very low (Pascual and Jovaní, [@B27]; Brannan and Jerrard, [@B3]; Courtney and Doherty, [@B5]).

In this study, we compared the sensitivity of the PCR--ESI--TOF--MS platform (Ibis Universal Biosensor; Abbott Molecular, Carlsbad, CA) (Ecker *et al.*, [@B6]) with traditional microbial cultural techniques to determine its possible role for rapid diagnoses of native joint septic arthritis and occult chronic bacterial infection associated with osteoarthritis (OA).

Patients and Methods {#s002}
====================

Patient populations {#s003}
-------------------

Ethical approval was obtained from the Allegheny Singer Research Institute Institutional Review Board. External funding was obtained from The Pittsburgh Foundation. Two cohorts of patients were analyzed, all of whom were admitted to a single level 1 teaching hospital: the first cohort consisted of patients requiring an orthopedic consultation for knee effusion who were suspected of septic arthritis requiring aspiration (44 pts); the second cohort consisted of patients undergoing elective primary total knee arthroplasty (21 pts) for OA. Informed consent was obtained before specimen acquisition from all patients. Exclusion criteria for the septic arthritis cohort included patients who were unable to provide informed consent, pregnancy, children under the age of 18, or a dry aspirate. Exclusion criteria for the OA cohort included a history of septic arthritis or a dry aspirate.

Clinical specimens {#s004}
------------------

All samples for the septic arthritis cohort were collected during diagnostic aspiration at the bedside by a single orthopedic surgeon (M.P.P.) to ensure consistency in specimen acquisition. The knee area was prepped with betadine and an 18 G needle was inserted using a standard superior-lateral approach. The aspirate was divided into two aliquots. The first aliquot was processed for routine laboratories: Gram stain, bacterial culturing, cell count with white blood cell differential, crystal analysis, protein levels, and glucose levels. The second aliquot was analyzed for the composition and diversity of microbes using the PCR−ESI--TOF--MS MDx (Ecker *et al.*, [@B6]) and/or for direct microscopic visualization of bacterial biofilms by 16S rRNA fluorescence *in situ* hybridization (FISH) using species- or genus-specific probe sets (Nistico *et al.*, [@B24], [@B23]).

All samples obtained from the OA cohort were collected by a single orthopedic surgeon (M.P.P.) in the operating room under sterile conditions after skin incision, using a sterile 18 G needle inserted using an antero-lateral approach, but before antibiotic administration and arthrotomy. Aspirated fluid, collected using sterile technique, was analyzed for the composition and diversity of microbes using MDx and/or for direct microscopic visualization of bacterial biofilms by FISH using species- or genus-specific probe sets.

Cultures and Gram stain {#s005}
-----------------------

Routine microbiological cultures were prepared by dipping a sterile swab into the aspirate and inoculating blood agar plates (BAP), chocolate agar plates (CHOC), MacConkey plates (MAC), and Columbia colistin-nalidixic acid agar. The agar plates were then incubated in 5% CO~2~ at 35°C. A second set of plates were inoculated after a blind broth subculture in thioglycolate media (THIO). The BAP and CHOC were incubated in 5% CO~2~ at 35°C, and the MAC and THIO were incubated in the aerobic incubator at 35°C. If growth was seen on plates after the first 24 h, then the sample was reincubated on plates and in broth for an additional 24 h. After day 2, if no growth was seen in broth or plates, the plates were discarded and reported as no growth day 2 and the THIO was placed in the rack for an additional 3 days. All significant isolates were reported on day 2, and any relevant plates were saved until day 5. If there was no growth on the plates, but growth in THIO, the THIO was Gram stained and subcultured on appropriate plates based upon the findings. The THIO was examined every 24 h until 5 days, and if no growth was found, no growth day 5 was reported. All plates were followed until day 5 and then disposed.

A Gram stain from the original aspirate was prepared by rolling a second swab on a glass slide to make a thin film. All slides made for Gram stain were examined for cells and bacteria under an oil immersion objective. Any polymorphonuclear leukocytes and mononuclear cells were reported. Any bacterial organisms seen were reported and quantified numerically.

Crystal analyses for gout and pseudogout {#s006}
----------------------------------------

Synovial fluid aspirate samples from all patients in both cohorts were analyzed for crystals by placing a drop of the synovial fluid sample on a glass slide and viewing under a high-powered microscope. The presence of rhomboid-shaped positively birefringent crystals was recorded as (+) for calcium pyrophosphate deposition (pseudogout). The presence of needle-shaped negatively birefringent crystals was recorded as (+) for monosodium urate crystals (gout). The lack of crystals was recorded as negative result.

Aspirate acquisition and preparation for MDx {#s007}
--------------------------------------------

Immediately after acquisition, the specimens were aliquoted and the aliquot for MDx was stored at −80°C. A second aliquot for bacterial 16S rRNA FISH was fixed with fresh 4% paraformaldehyde (PFA) and incubated for 2--4 h at 4°C. After the PFA incubation, the specimen was spun down and the supernatant removed. This process was repeated twice. Finally the samples were resuspended in 50% ethanol--phosphate-buffered saline solution and stored at −20°C before the 16S FISH evaluation.

MDx BAC assay for eubacterial detection and species identification using the Ibis T5000 platform {#s008}
------------------------------------------------------------------------------------------------

In summary, total DNA was extracted from aspirates and the bacterial DNAs were amplified by PCR (7) using the 17 primer pair BAC system developed by Ibis (Ecker *et al.*, [@B6]), and the individual amplicons were weighed using the Ibis T5000 platform. The species identities of the amplicons were then revealed using a database containing base composition data on virtually all bacterial species sequenced to date.

For each set of MDx analyses, multiple (two or three) negative controls were included that were processed identically to the clinical specimens using all of the same processing reagents and materials, except that no clinical material was added. Any bacterial species identified in the negative controls that also were detected in any of the clinical specimens were not included in the results. Although we did identify some organisms previously recognized as low-level contaminants in some of the commercial reagents, we did not identify any known pathogens in these controls. In addition, processing of clinical specimens and reaction setups were conducted in laboratories that were both physically and heating ventilation and air conditioning isolated from the amplification and analysis laboratories to minimize any risk of end product carryover contamination (Ehrlich and Greenberg, [@B10]). For all Ibis analyses, 1 mL of aspirate was centrifuged at 10,000 rpm × 3 min, then 900 μL of supernatant was removed leaving the bacteria in 100 μL. Two hundred seventy microliters of ATL lysis buffer (Qiagen, Germantown, MD; cat\# 19076) and 30 μL of proteinase K (Qiagen; cat\# 19131) were then added. Samples were incubated at 56°C for 1 h for proteolysis. One hundred microliters of a mixture containing 50 μl each of 0.1- and 0.7-mm Zirconia beads (Biospec; cat\# 11079101z, 11079107zx, respectively) was added to the samples, which were then homogenized for 10 min at 25 Hz using a Qiagen Tissuelyser. Nucleic acids from the lysed samples were then extracted using the Qiagen DNAeasy Tissue kit (Qiagen; cat\# 69506). Ten microliters of each sample was loaded per well onto the Ibis BAC detection PCR plate (Abbott Molecular; cat\# PN 05 N13-01). The BAC detection plate is a 96-well plate, which contains 17 primer pairs per assay that survey all bacterial organisms by using omnipresent loci (e.g., 16S rDNA sequences); phylum/class/order-specific loci; and some are targeted to specific pathogens of interest (e.g., the *Staphylococcus*-specific tufB gene). The system also detects the presence of several key antibiotic resistance markers: van A and van B (vancomycin resistance) in *Enterococcus* species, KPC (carbapenem resistance) in gram-negative bacteria, and mec A (methicillin resistance) in Staphylococcal species. An internal calibrant of synthetic nucleic acid template is also included in each assay, controlling for false negatives (e.g., from PCR inhibitors) and enabling a semiquantitative analysis of the amount of template DNA present. PCR amplifications were carried out as per Ecker *et al.* ([@B6]) (Courtney and Doherty, [@B5]) and the PCR products were then desalted in a 96-well plate format and sequentially electrosprayed into a TOF mass spectrometer. The spectral signals were processed to determine the masses of each of the PCR products present with sufficient accuracy that the nucleotide base composition of each amplicon could be unambiguously deduced. Using combined base compositions from multiple PCRs, the identities of the pathogens and a semiquantitative determination of their relative concentrations in the starting samples were established by using a proprietary algorithm to interface with the Ibis database of known organisms (Abbott Molecular).

Fluorescent *in situ* hybridization {#s009}
-----------------------------------

Specimens with discordant cultural and Ibis MDx results were further analyzed by FISH, which was performed as described by Nistico *et al.* ([@B24], [@B23]), in an attempt to confirm the positive MDx results in the cases of MDx positive/culture negative or to adjudicate in cases where the two techniques reported different positive results. Briefly, fixed aspirates were attached to gelatin-coated Shandon Multispot microscope slides (Thermo Electron Corporation, Waltham, MA). When detecting gram-positive bacteria by FISH, a solution of 0.1 mg/mL lysozyme (Sigma) in 0.1 M Tris HCl pH 7.5 and 0.05 M Na~2~EDTA was added to the specimens and incubated at 37°C for 3 h as an additional permeabilization step. Fixed permeabilized samples were then dehydrated in an ethanol series of 80% and 100% for 3 min each and FISH was performed with fluorescently tagged 16S rRNA oligonucleotide probes. The pan-eubacterial probe (EUB338) was used as a positive control. In addition, species-specific and genus-specific probes were chosen/designed to detect the following bacteria: (1) all; (2) *Staphylococcus* sp.; (3) *Staphylococcus aureus*; (4) *Streptococci* sp., (5) *Propionibacterium acnes*; or (6) *Enterococcus faecalis* (Integrated DNA Technologies, Inc., Coralville, IA) ([Table 1](#T1){ref-type="table"}). All probes were conjugated with one or the other of the sulfoindocyanine dyes, Cy3 or Cy5. Eubacterial (EU338) and nonsense probes (NONEUB338) were used as positive and negative controls, respectively. Each sample was incubated with probe-specific formamide and salt concentrations and then immersed in washing buffer with the probe-specific salt concentration. Samples were rinsed in sterile MilliQ water and observed with confocal laser scanning microscopy (CLSM).

###### 

[16S Ribosomal Ribonucleic Acid Fluorescent *in Situ* Hybridization Probe, DNA Sequence, and Associated Bacterial Target]{.smallcaps}

  *Probe*       *16S sequence*               *Target*
  ------------- ---------------------------- ---------------------------
  Eub338        GCTGCCTCCCGTAGGAGT           All bacteria
  NONEUB338     ACTCCTACGGGAGGCAGC           Nonsense sequence
  Sta           TCCTCCATATCTCTGCGC           *Staphylococcus* sp.
  Str           CACTCTCCCCTTCTGCAC           *Streptococcus* sp.
  Sau           GAAGCAAGCTTCTCGTCCG          *Staphylococcus aureus*
  PAC 16S 598   GCC CCA AGA TTA CAC TTC CG   *Propionibacterium acnes*
  ENF 191       GAAAGCGCCTTTCACTCTTATGC      *Enterococcus faecalis*

Confocal laser scanning microscopy {#s010}
----------------------------------

CLSM imaging was performed as described previously (Nistico *et al.*, [@B24], [@B23]), Briefly, after staining, the samples on the slide were imaged with a Leica DM RXE microscope attached to a TCS SP2 AOBS confocal system (Leica Microsystems; Exton, PA) using either a 40× (numerical aperture \[NA\] 1.25) or a 100× (NA 1.4) oil immersion lens.

Statistics {#s011}
----------

The difference in bacterial detection rates between standard cultural methods and the Ibis MDx was tested by McNemar\'s test, with the null hypothesis that the probability of a sample being culture negative, but MDx positive, is equal to the probability of a sample being culture positive, but MDx negative. The exact 2 × 2 package in statistical software R was used to calculate an exact *p*-value for McNemar\'s test (R Core Team, [@B28]; Fay, [@B12]). The chi-squared test was used to test for the association between positive detection by MDx and clinical diagnosis of septic arthritis as well as between positive detection by culture method and clinical diagnosis of septic arthritis. All graphical displays describing the distribution of bacteria were generated in graphics package of R (R Core Team, 2002).

Results {#s012}
=======

Between October 2010 and January 2013, 65 consecutive synovial fluid aspirate samples from patients consenting to participate in the study were analyzed. There were 44 from the septic arthritis patients and 21 OA patients. Patients included in the septic arthritis cohort had all been admitted to the hospital and presented with at least one symptom/sign for septic arthritis of a native knee, including effusion, pain, redness, fever, bacteremia, and elevated blood markers (erythrocyte sedimentation rate \[ESR\], C-reactive protein \[CRP\], and white blood cell \[WBC\]) ([Table 2](#T2){ref-type="table"}). Bacteria were detected by the PCR--ESI--TOF--MS (MDx) in 22/44 (50%) of the suspected septic arthritis samples and 6/21 (29%) of the OA samples ([Fig. 1](#f1){ref-type="fig"}). Culture detected only *S. aureus* in 6/44 septic arthritis samples and no bacteria in any OA cases. Thus, the MDx method detected bacteria in 28/65 (43%) total specimens, whereas standard microbial culture methods detected bacteria in 6/65 (9.2%) total specimens. We found the probability of culture negative, but MDx positive, was greater than the probability of culture positive, but MDx negative (*p*-value \<0.0001); this suggests that MDx are more likely to detect the bacterial presence than standard cultural methods. Neither the MDx nor culture produced results that were significantly correlated with the physicians\' suspicions of septic arthritis (*p* = 0.173 and *p* = 0.186, respectively).

![Microbial composition of synovial fluid using polymerase chain reaction--electrospray ionization--time-of-flight mass spectrometry (IBIS) for molecular diagnosis represented as a heat map. *Colored squares* represent a detection of species (*row*) in a patient (*column*) with different *colors* associated with the number of genomes per well; in addition, the presence of methicillin resistance genes (mecA) is also denoted. The *red line* denotes the separation of experimental (*left*) and control (*right*) sets. The numbers on the *right* margin indicate the frequency of species in all samples. Experimental refers to the patient cohort with suspected septic arthritis, and control refers to the patient cohort with osteoarthritis.](fig-1){#f1}

###### 

[Clinical Characteristics of Study Patients (Added in Revision)]{.smallcaps}

  *Study \#*   *Dx*   *WBC*   *ESR*   *CRP*   *SYN WBC*                               *% PMN*   *Protein*   *Glu*   *Crystal*   *Cx*       *Ibis*
  ------------ ------ ------- ------- ------- --------------------------------------- --------- ----------- ------- ----------- ---------- -------------
  NK1002       SA     7       NA      NA      12,750                                  83        5.1         70      Neg                    *Sa*
  NK1005       SA     19.6    \>140   26.7    not enough fluid to send for analysis   MRSA      MRSA                                       
  NK1006       SA     8.2     NA      NA      1250                                    95        2.7         122     Gout                   Neg
  NK1007       SA     9.9     67      8.3     2425                                    70        4           119     Gout                   *Sa*
  NK1008       SA     13.7    3       2.1     3600                                    94        3.7         57      Neg         *Sa*       Sa
  NK1009       SA     12.8    30      6.7     50                                      54        1.3         89      Neg                    Neg
  NK1010       SA     NA      NA      NA      8750                                    4         4.7         29      Neg                    Neg
  NK1011       SA     7.6     79      21.7    36,000                                  75        6.4         89      Neg                    *Se*
  NK1012       SA     9.5     74      15.7    35,500                                  86        6.9         146     Neg                    Neg
  NK1013       SA     9.2     4.6     62      6150                                    91        6.2         218     Neg                    Neg
  NK1014       SA     8       78      10.5    6120                                    89        3.7         82      Neg                    Neg
  NK1015       SA     11.3    NA      26      6                                       55        0.3         128     Neg                    *Sa*
  NK1016       SA     12.6    \>140   26.1    165,000                                 98        5.6         \<2     Neg                    Neg
  NK1017       SA     9.2     21      5.9     18,500                                  90        5.1         55      Gout                   *Sa*
  NK1023       SA     7.4     10      20.8    16,000                                  99        3.3         119     Gout                   *Pa*
  NK1025       SA     10.2    \>140   29.9    76,000                                  95        5.3         27      Neg         MRSA       *Strep ag*
  NK1026       SA     3.9     NA      NA      300,000                                 57        5.2         80      Neg                    *Neg*
  NK1030       SA     7.3     NA      NA      4600                                    86        3.1         195     Neg                    *Ef*
  NK1031       SA     1.2     NA      NA      4500                                    70        NA          NA      Neg                    *Neg*
  NK1035       SA     8.1     18      7.8     2333                                    87        2.6         162     Neg                    MRSA
  NK1036       SA     23.3    33      21.5    210,000                                 73        4.3         2       Gout        MRSA       MRSA
  NK1044       SA     8.2     92      19.6    13,000                                  87        3.8         93      Gout                   *Sh*
  NK1053       SA     18.7    68      37.1    20,000                                  81        4.5         45      Neg         MRSA       MRSA
  NK1055       SA     7.5     4       1.2     1100                                    94        2.5         162     Gout                   *Sc*
  NK1058       SA     4.9     55      \<0.3   23,000                                  95        2.6         131     Neg                    *ND*
  NK1059       SA     10.1    NA      NA      12,000                                  90        3.6         62      Neg                    *Neg*
  NK1064       SA     8.4     34      12.2    58,500                                  90        2           140     Gout                   *Neg*
  NK1065       SA     23.7    84      31.4    29,500                                  95        3.9         114     Neg                    *Neg*
  NK1066       SA     NA      NA      NA      9300                                    77        4           70      Neg                    *Lm*
  NK1069       SA     6.2     NA      NA      14,750                                  77        3.9         212     Gout                   *Neg*
  NK1070       SA     12.7    63      13.5    90,000                                  86        5.5         \<2     Neg         *S.* sp.   *Se and Sl*
  NK1071       SA     4.4     NA      NA      NA                                      NA        2.2         88      Neg                    *Neg*
  NK1072       SA     6.5     32      1.8     550                                     46        NA          NA      NA                     *Neg*
  NK1073       SA     6.4     54      5.6     1600                                    77        7.5         31      Neg                    *Neg*
  NK1075       SA     NA      NA      NA      300                                     8         4.1         16      Neg                    *Neg*
  NK1076       SA     8.8     66      10.6    15,000                                  84        4.2         183     Neg                    *Neg*
  NK1077       SA     8.8     66      10.6    14,000                                  86        3.8         168     Neg                    *Bt*
  NK1078       SA     9.9     59      5.1     11,000                                  91        4.4         148     Neg                    *Neg*
  NK1079       SA     12.5    18      12.8    41,000                                  84        3.6         492     Gout                   *Neg*
  NK1080       SA     5.9     21      2.7     29,000                                  81        4.6         130     CPPD                   *Strep py*
  NK1081       SA     21      60      25.8    41,500                                  93        4.5         109     Gout                   *Nm*
  NK1082       SA     21      60      25.8    28,875                                  95        3.7         97      Gout                   *Nm*
  NK1083       SA     13      NA      NA      26,250                                  96        4.3         153     Gout                   *Neg*
  NK1084       SA     8       64      26.2    29,750                                  91        2.2         134     Gout                   *Neg*
  NK1085       SA     6       56      3.8     48,125                                  63        2.4         100     Neg                    *Pa*
  NK1086       SA     6.6     17      2.8     5778                                    48        3.6         99      Neg                    *Neg*
  NK1061       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1062       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1067       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1068       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1087       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1088       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1089       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1090       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Se*
  NK1091       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1092       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Pa*
  NK1093       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1094       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Sc*
  NK1095       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1096       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1097       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1098       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1099       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Ch*
  NK1100       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Nm*
  NK1101       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Pa*
  NK1102       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*
  NK1103       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *ND*
  NK1105       OA     ND      ND      ND      ND                                      ND        ND          ND      ND                     *Neg*

Study \#, study number; Dx, clinical diagnosis or suspected clinical diagnosis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; SYN WBC, synovial white blood cell count; % PMN, percent polymorphonuclear leukocytes; Protein, protein concentration; glucose, glucose concentration; crystals, type of crystal if any found; Cx, positive microbiological culture result from synovial fluid; MRSA, methicillin-resistant *Staphylococcus aureus*; SA, septic arthritis; OA, osteoarthritis; NA, not assessed; ND, not determined based on diagnosis of osteoarthritis; neg, negative for any crystals; gout, positive for monosodium urate crystals; *Sa*, *Staphylococcus aureus*; *Se*, *Staphylococcus epidermidis*; *Pa*, *Propionibacterium acnes*; *Strep ag*, *Streptococcus agalactiae*; *Ef*, *Enterococcus faecalis*; *SH*, *Staphylococcus hominis*; *Sc*, *Staphylococcus capitas/caprae*; *Lm*, *Listeria monocytogenes*; *S.* sp., *Staphylococcus* species; *Sl*, *Staphylococcus lugudensis*; *Bt*, *Bacillus thuringiensis*; *Strep py Streptococcus pyogenes*; *Nm*, *Neisseria meningitides*; *Ch*, *Campylobacter hyointestinalis.*

MDx indicated that *S. aureus* was much more highly prevalent in the septic arthritis population 10/44 (22.7%) compared with the OA group 0/21 (0%). The next most frequent bacterium detected was *P. acnes*, present in two septic arthritis samples and two OA samples. Polymicrobial infections were identified in three specimens, two from the septic arthritis cohort and one from the OA group ([Fig. 2](#f2){ref-type="fig"}).

![Distribution of bacteria identified by MDx per encounter. **(i)** Experimental (septic arthritis) group (*n* = 44) and **(ii)** the control (osteoarthritis) group (*n* = 21). MDx, molecular diagnostics.](fig-2){#f2}

Five of the six *S. aureus* culture-positive samples were also *S. aureus* positive by MDx. The only patient who showed a discrepancy in detection was positive for *Streptococcus agalactiae* by MDx ([Table 3](#T3){ref-type="table"}). The detection of bacteria in a significantly higher percentage of cases in both patient cohorts by MDx compared with culture prompted the use of a confirmatory method to validate the discrepant MDx findings. Toward this end, FISH was performed on all MDx-positive/culture-negative specimens with one exception due to insufficient specimen. The FISH analyses confirmed the MDx result for 19/21 (90.5%) MDx-positive/culture-negative specimens ([Table 3](#T3){ref-type="table"}, blue and green, respectively, and [Fig. 3A](#f3){ref-type="fig"}). Four of the six samples that were positive by both MDx and culture were also subjected to FISH and CLSM-based visualization; as expected, these specimens were also FISH positive for *S. aureus* ([Table 3](#T3){ref-type="table"}, subset of purple; [Fig. 3B](#f3){ref-type="fig"}). Importantly, for the specimen (NK1025) with discrepant positive culture and positive MDx results, the FISH analyses performed independently with probes for both species supported the MDx finding of *Streptococcus agalactiae* and not *S. aureus*, supporting the conclusion that the culture was contaminated.

![Confocal microscopic images of biofilm bacteria labeled using FISH. The bacterial cells are visualized as *pink* in a *blue* (reflected light) background representing the synovial tissue taken from arthroscopic debridement and irrigation of two cases. **(A)** Sample NK1025 (osteoarthritis) stained with a *Streptococcus* sp.-specific FISH probe (*pink*). This specimen was MDx positive for *Streptococcus agalactiae*, but culture positive for *Staphylococcus aureus*. FISH performed on this specimen for *S. aureus* was negative. **(B)** Sample NK1092 (osteoarthritis) stained with *Propionibacterium acnes*-specific FISH probe (*pink*). FISH, fluorescent *in situ* hybridization.](fig-3){#f3}

###### 

[Results of Polymerase Chain Reaction--Electrospray Ionization--Time-Of-Flight Mass Spectrometry (IBIS), Fluorescent *in Situ* Hybridization, and Cultures for Each Patient Encounter that was IBIS or Fluorescent *in Situ* Hybridization Positive]{.smallcaps}

  ----------------
  ![](inl-1.gif)
  ----------------

*Blue* background highlighting indicates discordance between microbial culture and PCR-based DNA diagnostics (MDx) where the FISH results support the MDx result; *yellow* background highlighting indicates concordance of negative findings between microbial culture and MDx; *green* background highlighting indicates discordance between microbial culture and PCR-based DNA diagnostics (MDx) where the FISH results support the culture result; *purple* background highlighting indicates concordance of positive bacterial findings between microbial culture and MDx.

EUB, Pan-domain eubacterial probe (will hybridize with any bacterial 16S sequence); ND, not determined; PCR, polymerase chain reaction; FISH, fluorescent *in situ* hybridization; MDx, molecular diagnostics.

Utilizing 16S FISH as the gold standard, it demonstrates a specificity of 93% (26/28) for the PCR--ESI--TOF--MS MDx for bacterial detection in synovial fluid aspirates regardless of clinical diagnosis. Looking solely at the septic arthritis cohort, MDx had a specificity of 91% (21/23). It was not possible to assess sensitivity since all, but two, of the specimens examined by FISH were chosen based on their discordant MDx-positive and culture-negative results.

There was no correlation between the clinical laboratory parameters (cell count with white blood cell differential, presence or absence of crystals ([Fig. 4](#f4){ref-type="fig"}), protein levels, and glucose levels) and MDx findings. These findings suggest that while these parameters may be useful to detect host responses to highly virulent pathogens, they do not correlate with the presence or absence of microbes generally and chronic pathogens in particular.

![Comparison of clinical laboratory findings for gout and pseudogout (CPPD) crystals with MDx testing. *Left panel*: Crystal analysis of experimental (septic arthritis) group (*n* = 42) for CPPD and gout (uric acid); *right panel*: No correlation was found between CPPD or gout and bacterial identification on MDx. CPPD, calcium pyrophosphate dehydrate.](fig-4){#f4}
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Rapid detection and swift targeted treatment of septic arthritis are critically important to preserve articular cartilage (Mathews *et al.*, [@B21]). It is also important to prevent invasive spread of the infection to other musculoskeletal locations as well as to reduce the risk of systemic spread. Current diagnostic methods for septic arthritis rely on secondary signs of infection (WBC, CRP, ESR, synovial fluid analysis) and clinical judgment to initiate treatment while waiting for 24--120 h or more for culture results and antibiotic susceptibility profiles to be used for the rational selection of antimicrobial therapies (Pascual and Jovaní, [@B27]).

PCR--ESI--TOF--MS has the capability of providing both bacterial identification at the species level and antibiotic sensitivity predictions within 6 h of sample collection (Costerton *et al.*, [@B4]; Stoodley *et al.*, [@B31]). This improved efficiency could significantly reduce the potential complications of prolonged broad-spectrum antibiotic usage such as the development of increased antimicrobial resistance, *Clostridium difficile* colitis, and kidney damage, while significantly decreasing hospital costs.

In our study, all of the culture-positive cases were identified as *S. aureus*, consistent with historical findings (Mathews *et al.*, [@B21]). The MDx data confirmed the cultural findings in the majority of cases, which is also consistent with previous reports (Palmer *et al.*, [@B25], [@B26]). In the one culture-positive/MDx-positive species discrepant case (NK1025) the MDx finding of *Streptococcus agalactiae* was validated over the culture results using 16S rRNA FISH as an independent confirmatory method. A possible explanation for this discrepancy is that the patient was polyclonally infected and streptococci represented the vast majority of the sample such that any staphylococcal signal was below the detection threshold of MDx and FISH, alternatively the *S. aureus* finding may have resulted from contamination of the culture. The fact that positive MDx findings in the case of culture-negative cases did not always correlate with the laboratory results obtained for generic markers of inflammation is not surprising as the inflammatory response depends on the metabolic state of the bacteria (Ehrlich *et al.*, [@B9], [@B11]) and the immune status of the patient. Patients were hospitalized for a variety of reasons that could elevate inflammatory markers. Inflammatory responses to staphylococcal toxins do not correlate with the bacterial titers that are reported by the PCR--ESI--TOF--MS approach.

There were two septic arthritis cases with discordant MDx and FISH results. These could either reflect sampling error when performing FISH, as bacterial biofilms are known to be geographically nonhomogeneous (Hall-Stoodley *et al.*, [@B14]; Ehrlich *et al.*, [@B8]), or represent true false-positive results from the MDx.

Twenty-eight percent (6/21) of the specimens from patients with OA undergoing primary arthroplasty also contained bacteria that were detected by both the PCR--ESI--TOF--MS and 16S FISH. Not surprisingly, and in concordance with previous findings (Jacovides *et al.*, [@B17]), the bacterial species identified in the OA cases were different than those identified in the septic arthritis cases and represented slow-growing or opportunistic pathogens, including *P. acnes* and coagulase-negative staphylococci; organisms that do not necessarily promote purulent and pyogenic responses in the host.

Whereas it can be argued from a clinical perspective that all MDX-positive OA cases represent false positives as there are no overt signs or symptoms of infection, it is also quite clear from a microbiological perspective that there are bacteria present. These data are consistent with our previous observations (Jacovides *et al.*, [@B17]; Ehrlich *et al.*, [@B11]) that bacteria are often present in knees of osteoarthritic patients, but it must be emphasized that the clinical significance (if any) of these findings is unknown. We have speculated that bacteria in the knee joint of OA patients may play an etiological and/or exacerbatory role in the disease process, but unless these hypotheses can be substantiated mechanistically, their finding should probably not be used to initiate any type of antimicrobial treatment. These findings are consistent with studies that have shown that bacteria can survive within synovial cells (Shirtliff and Mader, [@B29]). However, it should be emphasized that these findings should be interpreted very cautiously with regard to making a diagnosis of septic arthritis. It is possible, however, through chronic or subacute processes (that do not induce standard inflammatory symptomatology by the host) that these infections do contribute to the pathogenesis of OA (Ehrlich *et al.*, [@B11]).

The most valuable data obtained from the present study may well be the finding that ∼50% of the patients with clinical suspicion of septic arthritis are negative by the PCR--ESI--TOF--MS methodology. Thus, future studies based on this finding could be designed to rapidly test suspected septic arthritis cases. Those patients who were MDx negative would be assigned to a watchful waiting status rather than treatment with broad-spectrum antibiotics.

One of the limitations of this study is the lack of follow-up clinical data on the OA patients with regard to their risk of subsequent periprosthetic joint infections based on their MDx status for bacterial presence. Thus, future studies should include a longitudinal component and animal models to determine the pathogenicity of the nonpurulent bacterial species identified by MDx.

In conclusion, based on its concordance with 16S bacterial FISH, the PCR--ESI--TOF--MS MDx has the potential to improve diagnostic accuracy and efficiency in the diagnosis and treatment of septic arthritis.
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